Nod to Ranbaxy for anti-malaria drug in Africa

Tribune News Service

New Delhi, December 15

Ranbaxy Laboratories has received regulatory nod to launch its indigenously developed anti-malarial drug Synriam in seven African nations.

The company has received regulatory approval to launch its first New Chemical Entity (NCE) Synriam in seven African countries — Nigeria, Uganda, Senegal, Cameroon, Guinea, Kenya and Ivory Coast, Ranbaxy said.

Ranbaxy CEO and MD Arun Sawhney said: “Most malaria cases and deaths occur in sub-Saharan Africa. Synriam is among the best options available today as it is highly effective, affordable and a convenient therapy option, leading to better compliance.”